Endobronchial coil therapy in severe emphysema: 6-month outcomes from a Swiss National Registry.

Details

Serval ID
serval:BIB_BF0D3A9C443F
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Endobronchial coil therapy in severe emphysema: 6-month outcomes from a Swiss National Registry.
Journal
Journal of thoracic disease
Author(s)
Fellrath J.M., Scherer T., Franzen D.P., Lovis A., von Garnier C., Plojoux J., Soccal P.M.
ISSN
2072-1439 (Print)
ISSN-L
2072-1439
Publication state
Published
Issued date
08/2018
Peer-reviewed
Oui
Volume
10
Number
Suppl 23
Pages
S2711-S2718
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Endobronchial coils have been demonstrated in three randomized, controlled trials to improve quality of life, exercise tolerance, and lung function in patients with severe emphysema. This therapy is CE-marked and commercially available in Switzerland. Coil treated patients are followed in a post-market Swiss registry to collect safety and effectiveness data in routine clinical practice.
The Swiss coil registry was initiated in October 2013. At the end of November 2016, an interim analysis of all 64 patients treated in five centers was performed to evaluate safety and effectiveness at six months post treatment.
patients had completed bilateral treatment with 6-month follow up at the time of data analysis. Patients had very severe, symptomatic emphysema and hyperinflation [38% male, mean age 66 years, BMI 24, FEV1 30% pred., residual volume (RV) 247% pred., 6-minute walking distance (6-MWD) 272 m, St. George Respiratory Questionnaire (SGRQ) 57 points]. Up to 6 months following treatment, seven serious adverse events (SAE) were reported in 6/29 patients. No device removals were necessary. At 6 months, responder rates [% achieving the minimal clinically important difference (MCID)] were as follows: RV (-0.35 L) 76%; FEV1 (+10%) 57%; SGRQ (-4 points) 87%; 6MWD (+26 m) 60%.
Endobronchial coil therapy performed in expert centers in Switzerland yields high 6-month responder rates across all relevant outcome.
Keywords
Chronic obstructive pulmonary disease (COPD), bronchoscopic lung volume reduction, coils, emphysema, registry
Pubmed
Web of science
Create date
24/09/2018 9:56
Last modification date
20/08/2019 16:33
Usage data